Endogenous antioxidants predicted outcome and increased after treatment: A benzoate dose‐finding, randomized, double‐blind, placebo‐controlled trial for Alzheimer's disease

AIM: Previous pilot studies suggest that sodium benzoate may be a potential cognitive enhancer for patients with Alzheimer's disease (AD), schizophrenia, or late‐life depression. Especially for AD treatment, a confirmatory trial with predictive biomarkers is urgently needed. This study aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Lane, Hsien‐Yuan, Wang, Shi‐Heng, Lin, Chieh‐Hsin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Regular Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099492/
https://www.ncbi.nlm.nih.gov/pubmed/36335573
http://dx.doi.org/10.1111/pcn.13504

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099492/
https://www.ncbi.nlm.nih.gov/pubmed/36335573
http://dx.doi.org/10.1111/pcn.13504

Ejemplares similares